Which super funds hold Dyne Therapeutics Inc?

As at 31 December 2025, 10 Australian super investment options in our dataset held Dyne Therapeutics Inc, the largest weighting being 0.01% in International Shares (Accumulation) (AustralianSuper).

Options holding it

10

Largest weighting

0.01%

International Shares (Accumulation) · AustralianSuper

Funds & options holding Dyne Therapeutics Inc

Australian super investment options disclosing a holding in Dyne Therapeutics Inc. Figures aggregate each option's disclosed line items for this security, as at each option's own reporting date.

FundPhaseOptionWeightingValue (AUD)As at
AustralianSuperAccumulationBalanced (Accumulation)
0.00%
$7,995,94931 December 2025
AustralianSuperAccumulationHigh Growth (Accumulation)
0.00%
$1,795,42031 December 2025
AustralianSuperRetirementBalanced (Income)
0.00%
$1,058,92731 December 2025
AustralianSuperAccumulationInternational Shares (Accumulation)
0.01%
$939,93431 December 2025
AustralianSuperRetirementConservative Balanced (Income)
0.00%
$219,50331 December 2025
AustralianSuperAccumulationConservative Balanced (Accumulation)
0.00%
$181,05331 December 2025
AustralianSuperRetirementInternational Shares (Income)
0.01%
$139,98331 December 2025
AustralianSuperRetirementHigh Growth (Income)
0.00%
$121,49631 December 2025
AustralianSuperAccumulationStable (Accumulation)
0.00%
$75,72531 December 2025
AustralianSuperRetirementStable (Income)
0.00%
$69,75331 December 2025

This page surfaces figures disclosed by the funds themselves under Portfolio Holdings Disclosure (Schedule 8D), each as at the date shown. It is factual disclosure information, not financial advice or a recommendation.

Methodology — how holdings are sourced, resolved and aggregated.

LookThrough shows the actual holdings inside Australian super funds, with cross-fund look-through.

  • 4 of 86 funds
  • 36 of 111 options reviewed
  • 7,010 of 7,168 securities reviewed

© 2026 LookThrough. Factual disclosure information — not financial advice, a rating or a recommendation.